肿瘤生物治疗网【官方网站】

专注于生物免疫治疗技术
当前位置: 首页 > 新闻 > 行业动态 >

开启更加给力免疫反应的蛋白质

时间:2014-06-16 14:39来源:生物谷 作者:网络 点击:
人体在首次受到病原体感染时给的免疫应答反应是缓慢而且是低烈度的,然而当人体再次受到该病原体感染,人体将会启动记忆细胞来进行高烈度,迅速的免疫应答反应。

  人体在首次受到病原体感染时给的免疫应答反应是缓慢而且是低烈度的,然而当人体再次受到该病原体感染,人体将会启动记忆细胞来进行高烈度,迅速的免疫应答反应。最近,Wistar研究所的研究人员发现,一种名为Foxp1的蛋白是抗体应答免疫反应过程中非常重要的组分。对该蛋白施加作用将为治疗免疫疾病开拓新的视野。Foxp1在免疫应答过程中的主要作用是协助激活CD4 T细胞,从而加强B细胞产生抗体以进行免疫反应。因此Foxp1蛋白是一种T细胞调控因子。受到Foxp1调控的T细胞是一种称为T Follicular Helper (TFH)的免疫T细胞,该类T细胞的主要功能是激活效应B细胞高烈度,和长效的免疫应答反应。Foxp1蛋白具有DNA结合位点,可以调控T细胞内基因的表达。因此,对Foxp1的抑制或者激活可以用来对免疫疾病和感染疾病进行治疗。该研究成果发表在了最新一期的Nature Immunology杂志上。

  详细英文报道:

  Your first response to an infectious agent or antigen ordinarily takes about a week, and is relatively weak. However, if your immune system encounters that antigen a second time, the so-called memory response is rapid, powerful, and very effective.

  Now, a team of researchers at The Wistar Institute offers evidence that a protein, called Foxp1, is a key component of these antibody responses. Manipulating this protein's activity, they say, could provide a useful pathway to boosting antibody responses to treat infectious diseases, for example, or suppressing them to treat autoimmune disorders. Their findings appear online in the journal Nature Immunology.

  "Foxp1 has an important role in our antibody immune responses, and if we could find a way to regulate Foxp1 activity in a subset of T cells, the CD4+ T cells, it could have some profound impact on the antibody responses," said Hui Hu, Ph.D., senior author of the study and associate professor at Wistar's National Cancer Institute-designated Cancer Center.

  "Repressing Foxp1 activity, for example, we may be able to make antibody responses faster-acting and more effective, which could be crucial in, say, a pandemic when time is a critical factor," Hu said. "Alternatively, if we could enhance the effectiveness of this protein, we may be able to significantly dampen the antibody responses that are unwanted in some cases of autoimmune diseases such as lupus."

  Previously, the Hu laboratory determined that Foxp1 was responsible for keeping T cells -- the white blood cells that mediate our immune system -- on "active stand-by mode," a process called quiescence. In the present study, Hu teamed with the laboratories of Louise C. Showe, Ph.D., professor in the Wistar Cancer Center's Molecular and Cellular Oncogenesis program, which provided crucial genomics expertise, and Jan Erickson, Ph.D., professor in the Tumor Microenvironment and Metastasis program, which offered expertise in the study of autoimmunity and the activation of B cells, the cells that generate antibodies.

  According to their Nature Immunology report, variants (or isoforms) of Foxp1 (called Foxp1A and Foxp1D) are critical regulators for the formation of a type of T cells, called T Follicular Helper (TFH) cells. These TFH cells then go on to enable B cells in creating long-lived, highly reactive antibodies. The proteins are transcription factors, meaning they work by binding to DNA to control which genes in these T cells are "read" or translated into protein.

  In the initial days of an immune response, the Foxp1 proteins determine how TFH cells arise from activated T cells. "The two isoforms act as regulators of TFH differentiation in the early moments of the immune response, where they effectively act as gatekeepers to slow TFH development, " Hu said. "They constitute a 'double-check' system that prevents the humoral branch of the immune system from acting too hastily."

(责任编辑:donggua)
相关文章
可减缓卵巢癌扩散的遗传途径 开启更加给力免疫反应的蛋白质 北科生物开展三标一体管理体系 新的白血病治疗策略可显著降低 探秘亚洲最大 细胞资源储存库 我科学家获抗癌抗病毒新突破 癌细胞药物敏感性的最佳预测算 深圳市北科生物治疗技术临床转
DC-CIK生物细胞免疫疗法,精确杀灭癌细胞,修复调整免疫细胞
生物治疗获冕诺贝尔医学奖桂冠
疾病症状
肝癌 肺癌 乳腺癌 胃癌 肠癌 肾癌 膀胱癌 胰腺癌 脑瘤 卵巢癌 食道癌 白血病 皮肤癌 淋巴瘤 鼻咽癌 黑色素瘤